ConSynance’s Prader-Willi Syndrome Treatment Gains Designation from FDA

ConSynance Therapeutics has received a rare paediatric illness classification from the FDA for its oral medicine for the treatment of Prader-Willi syndrome.

According to the classification, in the event that the FDA approves the medication candidate, CSTI-500, the US-based business will be qualified to get a priority review voucher.

The serotonin, dopamine, and norepinephrine balance linked to these actions is restored by CSTI-500. In a press statement, the business claims that CSTI-500 is the first treatment in the field that tackles these syndrome signs.

Presently, Prader-Willi syndrome children are advised to take hormones that promote growth. These can support the transformation of the face look, boost energy levels, and enhance muscular development and strength.

ConSynance CEO Shuang Liu stated: “CSTI-500 stands out as the first drug candidate for Prader-Willi syndrome designed to address both hyperphagia and severe temper outbursts, providing a potential breakthrough and comprehensive treatment solution for this challenging disorder.”